抄録
The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 7597-7600 |
| ページ数 | 4 |
| ジャーナル | Antimicrobial agents and chemotherapy |
| 巻 | 58 |
| 発行部数 | 12 |
| DOI | |
| 出版物ステータス | Published - 01-12-2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
これを引用
}
KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-. / Bremmer, Derek N.; Clancy, Cornelius J.; Press, Ellen G.; Almaghrabi, Reem; Chen, Liang; Doi, E. Yohei; Nguyen, M. Hong; Shieldsb, Ryan K.
：: Antimicrobial agents and chemotherapy, 巻 58, 番号 12, 01.12.2014, p. 7597-7600.研究成果: Article
TY - JOUR
T1 - KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-
AU - Bremmer, Derek N.
AU - Clancy, Cornelius J.
AU - Press, Ellen G.
AU - Almaghrabi, Reem
AU - Chen, Liang
AU - Doi, E. Yohei
AU - Nguyen, M. Hong
AU - Shieldsb, Ryan K.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.
AB - The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.
UR - http://www.scopus.com/inward/record.url?scp=84912101206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84912101206&partnerID=8YFLogxK
U2 - 10.1128/AAC.03831-14
DO - 10.1128/AAC.03831-14
M3 - Article
C2 - 25288089
AN - SCOPUS:84912101206
VL - 58
SP - 7597
EP - 7600
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 12
ER -